A list of 10 medical devices entering the innovation channel, attracting more attention than usual?

Have friends in the medical circle noticed that the list of 10 medical devices entering the innovation channel announced by the NMPA on August 5th has attracted more attention than usual?

Some people say this is just a routine public notice and there is no need to over-interpret it. However, a brief review of the technical features of these products reveals that they not only represent the cutting-edge direction of current medical device innovation but are also likely to transform the clinical diagnosis and treatment model in the next 3 to 5 years.

This gives rise to several issues worthy of attention:

• Which clinical pain points have these products actually addressed?

• In which fields are technological breakthroughs concentrated?

• What signals does it send for the development of the industry?

Let's look at them one by one.

First of all, what long-standing clinical problems have these products solved?

From the perspective of tumor treatment, for a long time, complex tumor surgeries have been confronted with the predicament of "high trauma and high risk".

For a long time, complex tumor surgeries have been confronted with the predicament of "high trauma and high risk". For instance, in liver cancer and pancreatic cancer surgeries, traditional radiofrequency or cryoablation can easily damage peripheral blood vessels and nerves, leading to slow postoperative recovery for patients and making it difficult for primary hospitals to carry out such procedures.

• Hangzhou Weina Anke's steep pulse ablation instrument: It uses a high-voltage ultra-short pulse electric field to achieve non-thermal ablation, precisely avoiding "forbidden zones" such as blood vessels and nerves. Moreover, the "single-needle local anesthesia" surgical method compressors the operation time to within 15 minutes, significantly enhancing the safety and popularity of the surgery.

• Novokule's tumor electric field therapy device: Offering a new option for patients with glioblastoma. The release of medium-frequency electric fields through wearable devices to interfere with the division of cancer cells has been verified to prolong the survival period of patients. Its potential in combination with PD-1 and chemotherapy may become the focus of subsequent clinical research.

• Looking at the field of cardiovascular diseases, traditional mechanical or biological valves have a contradiction between "lifespan and anticoagulation", making postoperative management difficult for patients over 70 years old.

• The transcatheter aortic valve system of Shanghai Yixin Medical: As the world's first polymer valve, the 38-month clinical follow-up data shows that the thrombosis rate is 40% lower than that of biological valves. The fully automated production process can also reduce the cost to the level of a thousand yuan, which is very beneficial for popularization at the grassroots level.

• Xianjian Technology's nickel-titanium alloy patent ductus arteriosus occluder: Designed for pediatric patients, the degradable material avoids the problem of carrying metal implants for life. The 6F delivery system diameter even enables minimally invasive intervention for newborns, which is an important advancement in the treatment of complex congenital heart diseases.

• Morningside Medical's atrial septal foramen atrial shunt: Targeting the "blue ocean" of heart failure treatment, it reduces left atrial pressure through foramen formation. Compared with drug treatment, it can improve symptoms more quickly, but its long-term cardiac function improvement data still needs further attention.

In the field of AI and chronic disease management, Guangzhou Aiyunji's prenatal ultrasound AI diagnosis software has raised the recognition sensitivity of nine major fetal malformations, including craniocerebral malformations, to over 95%. This not only enhances diagnostic efficiency but also promotes the standardization of prenatal screening, which is of great significance in reducing the rate of birth defects.

• The prenatal ultrasound AI diagnosis software of Guangzhou Aiyunji has raised the recognition sensitivity of 9 major fetal malformations, including craniocerebral malformations, to over 95%. This not only enhances the diagnostic efficiency but also promotes the standardization of prenatal screening, which is of great significance in reducing the rate of birth defects.

• Shanghai Yiyu Technology's closed-loop insulin infusion system: It has achieved a fully automatic closed loop of "blood glucose measurement - drug administration", reducing manual intervention by 80% compared to traditional pumps. Patients' blood glucose fluctuations are smaller, and the risk of complications is lower. Its catheter-free patch design has been included in European medical insurance, and its global potential is worth looking forward to.

Secondly, in which fields are these technological breakthroughs concentrated?

From the above products, it can be seen that tumor treatment is making a leap from "invasive" to "non-invasive". The cardiovascular field takes material innovation and surgical simplification as its core competitiveness, while AI and chronic disease management have achieved a leap from "assistance" to "autonomous decision-making".

These fields are all directions with urgent clinical needs and high technical barriers, and they also reflect the characteristic of innovative devices focusing on clinical value.

What signal does this send for the development of the industry?

• The technical threshold has been raised again

Products that can enter the innovation channel are either "global firsts" (such as polymer valves) or address "clinical essential needs" (such as single-needle tumor ablation).

It is getting increasingly difficult to follow the trend in innovation. Enterprises need to make real breakthroughs in core technologies in order to gain a foothold in the competition.

• Clinical value has become the core evaluation criterion

Judging from the publicized information, the three questions of "whether trauma is reduced", "whether therapeutic effect is improved" and "whether cost is lowered" are the "compulsory questions" that innovative medical devices must confront.

This also guides enterprises to pay more attention to the actual clinical application value of their products during the research and development process, rather than merely pursuing technological novelty.

• Local enterprises are accelerating their breakthrough

1Among the 10 products, 8 are from Chinese enterprises, covering everything from AI diagnosis to high-end implant intervention. This indicates that domestic innovation has evolved from "single-point breakthroughs" to "full-chain capabilities", and its competitiveness in the international market is also constantly improving.

These products that enter the innovation channel usually go from public announcement to market launch 1 to 2 years faster than ordinary devices. For clinical practice, it means being able to use cutting-edge technologies more quickly. For the industrial end, the subsequent clinical data and commercialization paths of these 10 "seed players" are worth continuous tracking.

有There is a hunch that as these innovative devices are gradually implemented, the clinical diagnosis and treatment model may undergo new changes, and the medical industry will also enter a development stage that pays more attention to the quality of innovation. I wonder which product everyone is most looking forward to? Welcome to discuss together.